查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301022

藥物器械組合產品的市場規模、份額和趨勢分析報告：按產品（透皮貼劑、輸液泵、吸入器、藥物洗脫支架）、按地區、細分市場趨勢，2023-2030年

Drug Device Combination Products Market Size, Share & Trends Analysis Report By Product (Transdermal Patches, Infusion Pumps, Inhalers, Drug Eluting Stents), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10個工作天內

價格

藥物器械組合產品市場的增長和趨勢

根據Grand View Research, Inc.最新報告，到2030年，全球藥械組合產品市場規模將達到2518億美元，預計還將繼續增長年復合增長率為 8.9%。

由於與微創技術相關的患者治療效果得到改善，需求不斷增長，這是該市場的一個高影響力驅動因素。 這些設備有助於早期診斷並縮短大多數外科手術的治療時間。 需求不斷增長的另一個原因是這些設備帶來的痛苦最小、成本效率更高、安全性更高、功效更高、恢復更快和住院時間更短。

醫療保健監管機構越來越多地執行明確的上市前批准協議，預計將有助於製造商獲得其產品的批准。 最近，美國FDA採用了精益管理流程映射方法，創建了一個更具凝聚力、精簡、系統和協作的系統來審查上述產品。 據推測，這些當局發布的安全指南和建議將在未來增加這些產品的採用，並促進預測期內的整體增長。

由於藥物在體內非預期部位吸收，與治療藥物相關的嚴重副作用和藥物相互作用引發了對靶向治療的需求，從而推動了對藥物器械組合的需求。預計 例如，連續施用左旋多巴會導致長期並發症，例如運動波動、運動障礙、嚴重的代謝改變和神經毒性。 這些因素使得臨床上必須納入基於靶向治療的替代方案，例如藥物-器械組合產品。

藥物器械組合產品市場報告亮點

  • 由於對於需要長期治療的疾病的自我給藥需求不斷增加，透皮貼劑將在 2022 年佔據產品市場份額
  • 由於慢性病患病率上升，預計吸入器領域在預測期內將呈現 10.3% 的複合年增長率
  • 由於該地區領先企業開展了廣泛的新產品開發活動，北美地區在 2022 年佔據了最大的地區份額，超過 40.5%。
  • 由於醫療保健支出不斷增加以及醫生對這些產品益處的認識不斷提高，亞太地區預計未來幾年將以有利的速度增長。
  • 主要市場參與者正在製定各種策略，例如新產品發布和銷售合作夥伴關係，以獲得市場滲透。
  • 由於高昂的運營成本、嚴格的監管框架和資本要求，進入壁壘保持在較高水平。

內容

第一章調查方法及範圍

  • 調查方法
  • 調查範圍和假設
  • 數據源列表

第 2 章執行摘要

第三章市場概況

第四章市場變量、趨勢和範圍

  • 市場細分和範圍
  • 市場驅動因素分析
    • 對微創給藥設備的需求不斷增加
    • 技術進步
    • 現場護理治療日益普及
    • 政府醫療保健機構持續採取乾預措施
    • 意識水平提高
    • 完善醫療收費制度
  • 市場製約因素分析
    • 相關成本高
    • 藥物輸送的技術問題
  • 採用和增長前景圖
  • 製藥器械組合 - SWOT 分析，按因素（政治和法律、經濟和技術）
  • 行業分析-波特

第五章藥物器械組合產品市場：產品估算和趨勢分析

  • 藥物組合產品市場：產品變異分析
  • 輸液泵
    • 2018-2030 年輸液泵市場估計和預測（十億美元）
    • 體積測量
    • 一次性
    • 注射器
    • 門診
    • 可嵌入
    • 胰島素
  • 骨科手術組合產品
    • 2018-2030 年骨科組合產品市場估計和預測（十億美元）
    • 骨移植植入物
    • 抗生素骨水泥
  • 光動力治療儀
    • 2018-2030 年光動力治療設備市場估計和預測（十億美元）
  • 透皮貼劑
    • 2018-2030 年透皮貼劑市場估計和預測（十億美元）
  • 藥物洗脫支架
    • 2018-2030 年藥物洗脫支架市場估算和預測（十億美元）
    • 冠狀動脈支架
  • 傷口護理產品
    • 2018-2030 年傷口護理產品市場估計和預測（十億美元）
  • 吸入器
    • 2018-2030 年吸入器市場估計和預測（十億美元）
    • 乾粉
    • 霧化器
    • 固定劑量
  • 抗菌導管
    • 2018-2030 年抗菌導管市場估計和預測（十億美元）
    • 泌尿科
    • 心血管
    • 其他
  • 其他
    • 2018-2030 年其他市場估算和預測（十億美元）

第 6 章藥物器械組合產品市場：按產品劃分的區域估計和趨勢分析

  • 2022 年按地區劃分的藥物器械組合市場份額
  • 北美
    • 按產品劃分，2018-2030 年
  • 歐洲
    • 按產品劃分，2018-2030 年
  • 亞太地區
    • 按產品劃分，2018-2030 年
  • 拉丁美洲
    • 按產品劃分，2018-2030 年
  • MEA
    • 按產品劃分，2018-2030 年

第七章競爭格局

  • 戰略框架
  • 市場參與分類
  • 公司簡介
    • Abbott Laboratories
    • Terumo Corporation
    • Stryker Corporation
    • Mylan NV
    • Medtronic
    • St.Jude Medical, Inc.
    • Allergan, Plc
    • Boston Scientific Corporation
    • Novartis AG
    • Teleflex Incorporated
    • CR Bard, Inc.
    • WLCore &Associates, Inc.
Product Code: GVR-1-68038-260-0

Drug Device Combination Products Market Growth & Trends

The global drug device combination product market size is expected to reach USD 251.8 billion by 2030, according to a new report by Grand View Research, Inc., growing at a CAGR of 8.9% during the forecast period. Rising demand for minimally invasive techniques due to enhanced patient outcomes associated with it is the high impact-rendering driver of this market. These devices facilitate early diagnosis and reduce treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.

Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.

Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.

Drug Device Combination Products Market Report Highlights

  • Transdermal patch held the dominant share by product in 2022 owing to increasing demand for self-administration of drugs in diseases requiring long-term treatment
  • The inhalers segment is anticipated to exhibit a lucrative CAGR of 10.3% over the forecast period owing to rising prevalence of chronic diseases
  • North America held the largest share of over 40.5% in 2022 in terms of region owing to extensive new product development activities conducted by prominent players across this region
  • Asia Pacific is anticipated to grow at a lucrative rate over the coming years owing to increasing healthcare spending and rising awareness levels of physicians pertaining to benefits of these products
  • Key market players are engaged in various strategies such as new product launch and distribution agreements to gain market penetration
  • High operational cost, stringent regulatory framework, and capital requirement keep entry barriers at a higher level, owing to which, threat of new entrants is expected to be low.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Market Snapshot

Chapter 4. Market Variables, Trends & Scope

  • 4.1. Market segmentation & scope
  • 4.2. Market Driver Analysis
    • 4.2.1. Increasing demand for minimally invasive drug delivery devices
    • 4.2.2. Technological advancements
    • 4.2.3. Growing popularity of point of care treatment
    • 4.2.4. Consistent interventions by government healthcare organizations
    • 4.2.5. Increasing awareness levels
    • 4.2.6. Improving medical reimbursement framework
  • 4.3. Market Restraint Analysis
    • 4.3.1. High associated costs
    • 4.3.2. Technical challenges in drug delivery
  • 4.4. Penetration & Growth Prospect Mapping
  • 4.5. Drug Device Combination - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 4.6. Industry Analysis - Porter's

Chapter 5. Drug Device Combination Products Market: Product Estimates & Trend Analysis

  • 5.1. Drug device combination market: Product Movement Analysis
  • 5.2. Infusion Pumps
    • 5.2.1. Infusion pumps market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.2. Volumetric
      • 5.2.2.1. Volumetric market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.3. Disposable
      • 5.2.3.1. Disposable market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.4. Syringe
      • 5.2.4.1. Syringe market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.5. Ambulatory
      • 5.2.5.1. Ambulatory market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.6. Implantable
      • 5.2.6.1. Implantable market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.2.7. Insulin
      • 5.2.7.1. Insulin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Orthopedic Combination Products
    • 5.3.1. Orthopedic combination products market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.3.2. Bone graft implants
      • 5.3.2.1. Bone graft implants market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.3.3. Antibiotic bone cement
      • 5.3.3.1. Antibiotic bone cement market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Photodynamic Therapy Devices
    • 5.4.1. Photodynamic therapy devices market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Transdermal Patches
    • 5.5.1. Transdermal patches market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Drug Eluting Stents
    • 5.6.1. Drug eluting stents market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.6.2. Coronary stents
      • 5.6.2.1. Coronary stents market estimates and forecasts, 2018 - 2030 (USD Billion)
      • 5.6.2.2. Peripheral vascular stents market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Wound Care Products
    • 5.7.1. Wound care products market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.8. Inhalers
    • 5.8.1. Inhalers market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.2. Dry powder
      • 5.8.2.1. Dry powder market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.3. Nebulizers
      • 5.8.3.1. Nebulizers market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.8.4. Metered dose
      • 5.8.4.1. Metered dose market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Antimicrobial Catheters
    • 5.9.1. Antimicrobial catheters market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.2. Urological
      • 5.9.2.1. Urological market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.3. Cardiovascular
      • 5.9.3.1. Cardiovascular market estimates and forecasts, 2018 - 2030 (USD Billion)
    • 5.9.4. Others
      • 5.9.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Others market estimates and forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Drug Device Combination Products Market: Regional Estimates & Trend Analysis, By Product

  • 6.1. Drug Device Combination Market Share By Region, 2022
  • 6.2. North America
    • 6.2.1. North America market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.2.1.1. U.S. market estimates and forecasts
      • 6.2.1.2. Canada market estimates and forecasts
  • 6.3. Europe
    • 6.3.1. Europe market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.3.1.1. UK market estimates and forecasts
      • 6.3.1.2. Germany market estimates and forecasts
      • 6.3.1.3. France market estimates and forecasts
      • 6.3.1.4. Italy market estimates and forecasts
      • 6.3.1.5. Spain market estimates and forecasts
      • 6.3.1.6. Denmark market estimates and forecasts
      • 6.3.1.7. Sweden market estimates and forecasts
      • 6.3.1.8. Norway market estimates and forecasts
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.4.1.1. Japan market estimates and forecasts
      • 6.4.1.2. China market estimates and forecasts
      • 6.4.1.3. India market estimates and forecasts
      • 6.4.1.4. Australia market estimates and forecasts
      • 6.4.1.5. Thailand market estimates and forecasts
      • 6.4.1.6. South Korea market estimates and forecasts
  • 6.5. Latin America
    • 6.5.1. Latin America market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.5.1.1. Brazil market estimates and forecasts
      • 6.5.1.2. Mexico market estimates and forecasts
      • 6.5.1.3. Argentina market estimates and forecasts
  • 6.6. MEA
    • 6.6.1. MEA market estimates and forecasts, by product, 2018 - 2030 (USD Billion)
      • 6.6.1.1. South Africa market estimates and forecasts
      • 6.6.1.2. Saudi Arabia market estimates and forecasts
      • 6.6.1.3. UAE market estimates and forecasts
      • 6.6.1.4. Kuwait market estimates and forecasts

Chapter 7. Competitive Landscape

  • 7.1. Strategy framework
  • 7.2. Market participation categorization
  • 7.3. Company Profiles
    • 7.3.1. Abbott Laboratories
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Terumo Corporation
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Stryker Corporation
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Mylan N.V.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Medtronic
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. St.Jude Medical, Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Allergan, Plc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Boston Scientific Corporation
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Novartis AG
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Teleflex Incorporated
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. C.R. Bard, Inc.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. W.L.Core & Associates, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 3 U.S. drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 4 Canada drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 5 Europe drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 6 Germany drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 7 UK drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 8 France drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 9 Italy drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 10 Spain drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 11 Denmark drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 12 Sweden drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 13 Norway drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 14 Asia Pacific drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 15 Japan drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 16 China drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 17 India drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 18 Australia drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 19 Thailand drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 20 South Korea drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 21 Latin America drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 22 Brazil drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 23 Mexico drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 24 Argentina drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 25 MEA drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 26 South Africa drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 27 Saudi Arabia drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 28 UAE drug device combination market, by product, 2018 - 2030 (USD Billion)
  • TABLE 29 Kuwait drug device combination market, by product, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market summary (USD Billion)
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation & scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Penetration & growth prospect mapping
  • FIG. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • FIG. 8 Porter's five forces analysis
  • FIG. 9 Drug device combination market product outlook key takeaways
  • FIG. 10 Drug device combination market: Product movement analysis
  • FIG. 11 Global infusion pumps market, 2018 - 2030 (USD Billion)
  • FIG. 12 Global volumetric market, 2018 - 2030 (USD Billion)
  • FIG. 13 Global disposable market, 2018 - 2030 (USD Billion)
  • FIG. 14 Global syringe market, 2018 - 2030 (USD Billion)
  • FIG. 15 Global ambulatory market, 2018 - 2030 (USD Billion)
  • FIG. 16 Global implantable market, 2018 - 2030 (USD Billion)
  • FIG. 17 Global insulin market, 2018 - 2030 (USD Billion)
  • FIG. 18 Global orthopedic combination products market, 2018 - 2030 (USD Billion)
  • FIG. 19 Global bone graft implants market, 2018 - 2030 (USD Billion)
  • FIG. 20 Global antibiotic bone cement market, 2018 - 2030 (USD Billion)
  • FIG. 21 Global photodynamic therapy devices market, 2018 - 2030 (USD Billion)
  • FIG. 22 Global transdermal patches market, 2018 - 2030 (USD Billion)
  • FIG. 23 Global drug eluting stents market, 2018 - 2030 (USD Billion)
  • FIG. 24 Global coronary stents market, 2018 - 2030 (USD Billion)
  • FIG. 25 Global peripheral vascular stents market, 2018 - 2030 (USD Billion)
  • FIG. 26 Global wound care products market, 2018 - 2030 (USD Billion)
  • FIG. 27 Global inhalers market, 2018 - 2030 (USD Billion)
  • FIG. 28 Global dry powder market, 2018 - 2030 (USD Billion)
  • FIG. 29 Global nebulizers market, 2018 - 2030 (USD Billion)
  • FIG. 30 Global metered dose market, 2018 - 2030 (USD Billion)
  • FIG. 31 Global antimicrobial catheters market, 2018 - 2030 (USD Billion)
  • FIG. 32 Global urological market, 2018 - 2030 (USD Billion)
  • FIG. 33 Global cardiovascular market, 2018 - 2030 (USD Billion)
  • FIG. 34 Global others market, 2018 - 2030 (USD Billion)
  • FIG. 35 Global others market, 2018 - 2030 (USD Billion)
  • FIG. 36 Regional market place: Key takeaways
  • FIG. 37 Regional outlook, 2015 & 2024
  • FIG. 38 North America drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 39 U.S. drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 40 Canada drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 41 Europe drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 42 Germany drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 43 UK drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 44 France drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 45 Italy drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 46 Spain drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 47 Denmark drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 48 Sweden drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 49 Norway drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 50 Asia Pacific drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 51 Japan drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 52 China drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 53 India drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 54 Australia drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 55 Thailand drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 56 South Korea drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 57 Latin America drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 58 Brazil drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 59 Mexico drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 60 Argentina drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 61 MEA drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 62 South Africa drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 63 Saudi Arabia drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 64 UAE drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 65 Kuwait drug device combination market, 2018 - 2030 (USD Billion)
  • FIG. 66 Strategy framework
  • FIG. 67 Participant categorization